Cargando…
The unmet need for COVID-19 treatment in immunocompromised patients
BACKGROUND: Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. MAIN TEXT: The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antib...
Autores principales: | Alessandra, D’Abramo, Serena, Vita, Emanuele, Nicastri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742028/ https://www.ncbi.nlm.nih.gov/pubmed/36503419 http://dx.doi.org/10.1186/s12879-022-07918-x |
Ejemplares similares
-
Correction: The unmet need for COVID-19 treatment in immunocompromised patients
por: D’Abramo, Alessandra, et al.
Publicado: (2023) -
Monoclonal Antibodies for Pre- and Postexposure Prophylaxis of COVID-19: Review of the Literature
por: Vita, Serena, et al.
Publicado: (2022) -
Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021) -
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway
por: D’Abramo, Alessandra, et al.
Publicado: (2022) -
Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients
por: Vergori, Alessandra, et al.
Publicado: (2021)